Assessment of treatment response in tuberculosis
More about Open Access at the CrickAbstract
Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.
Journal details
Volume 10
Issue number 6
Pages 643-654
Publication date
Full text links
Publisher website (DOI) 10.1586/17476348.2016.1166960
Europe PubMed Central 27030924
Pubmed 27030924
Keywords
Related topics
Type of publication